Biomarker combination and kit for predicting repeated embryo implantation failure, application of biomarker combination, combined drug and application of combined drug

Through the combination of biomarkers (including LCN2, fibroblast-related factors and trNK cell populations) and combined drugs, the prediction and diagnosis and treatment problems of repeated embryo transplantation failures are solved, early risk identification and intervention in infertile women is achieved, and the opportunities for reproductive health are improved.

CN119689002AActive Publication Date: 2025-03-25SHANDONG UNIV
8 Cites 0 Cited by

Patent Information

Application Number
CN202510208434.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-02-25
Publication Date
2025-03-25
Estimated Expiration
2045-02-25

AI Technical Summary

Technical Problem

At this stage, there is a lack of effective prediction and diagnosis and treatment methods to solve the problem of repeated embryo transplantation failure, resulting in a high pregnancy failure rate for women with infertility in assisted reproductive treatment, resulting in waste of embryos and medical resources.

Method used

A biomarker combination, including lipid carrier 2 (LCN2) and fibroblast-associated factors such as FN1, COL3A1, and ZO-1, were proposed, as well as a population of trNK cells, to predict repeated embryo transplant failure. At the same time, a kit and combination drug were developed to predict and prevent repeated embryo transplant failures by detecting these markers and using these drugs.

Benefits of technology

This biomarker combination can accurately predict repeated embryo transplant failures, helping infertile women identify risks before intervention as early as possible, thereby improving opportunities for reproductive health. Combined drugs can be used to reduce the incidence of repeated embryo transplantation failure and have important clinical conversion value.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to the field of biology, and particularly provides a biomarker combination for predicting repeated embryo implantation failure, a kit, application of the biomarker combination, a combined drug and application of the combined drug, the biomarker combination comprises lipocalin 2 and at least one of trNK cell population and fibroblast related factors, the fibroblast related factors comprise at least one of FN1, COL3A1 and ZO-1. The biomarker combination disclosed by the invention can accurately predict the repeated embryo planting failure, can be used for predicting the risk of the repeated embryo planting failure of an infertility female patient suffering from the repeated planting failure, and is beneficial for the patient to intervene as early as possible, so that the fertility health of the female of the right age is guaranteed. The combined medicine disclosed by the invention can be used for preventing or treating and reducing the repeated embryo planting failure, and has important scientific research and clinical transformation values for the repeated embryo planting failure.
Need to check novelty before this filing date? Find Prior Art